CN116133657A - 治疗covid-19疾病的新组合物和方法 - Google Patents

治疗covid-19疾病的新组合物和方法 Download PDF

Info

Publication number
CN116133657A
CN116133657A CN202180033555.4A CN202180033555A CN116133657A CN 116133657 A CN116133657 A CN 116133657A CN 202180033555 A CN202180033555 A CN 202180033555A CN 116133657 A CN116133657 A CN 116133657A
Authority
CN
China
Prior art keywords
patient
composition
patients
antagonist
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033555.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·伯杰
I·迪潘
R·普雷维尔
C·詹姆斯
P-O·吉罗代
K·比兹姆斯
R·拉滕巴赫
J·布里敦
F·托泰因
V·森西奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bordeaux Medical Center
4 Active Biotechnology Co
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Bordeaux
Institut Pasteur
Universite de Lille
Original Assignee
Bordeaux Medical Center
4 Active Biotechnology Co
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Bordeaux
Institut Pasteur
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bordeaux Medical Center, 4 Active Biotechnology Co, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Bordeaux, Institut Pasteur, Universite de Lille filed Critical Bordeaux Medical Center
Publication of CN116133657A publication Critical patent/CN116133657A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180033555.4A 2020-05-07 2021-05-05 治疗covid-19疾病的新组合物和方法 Pending CN116133657A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173595.8A EP3906922A1 (en) 2020-05-07 2020-05-07 New compositions and methods of treating covid-19 disease
EP20173595.8 2020-05-07
PCT/EP2021/061919 WO2021224356A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease

Publications (1)

Publication Number Publication Date
CN116133657A true CN116133657A (zh) 2023-05-16

Family

ID=70617050

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033555.4A Pending CN116133657A (zh) 2020-05-07 2021-05-05 治疗covid-19疾病的新组合物和方法

Country Status (9)

Country Link
US (1) US20230157994A1 (https=)
EP (2) EP3906922A1 (https=)
JP (1) JP2023539542A (https=)
KR (1) KR20240073720A (https=)
CN (1) CN116133657A (https=)
AU (1) AU2021269090A1 (https=)
BR (1) BR112022022578A2 (https=)
CA (1) CA3177779A1 (https=)
WO (1) WO2021224356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
JP2023524522A (ja) * 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
WO2022197625A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197627A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197626A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用
WO2024092069A1 (en) * 2022-10-26 2024-05-02 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors for treatment of neurological diseases
CN121039852A (zh) 2023-06-07 2025-11-28 株式会社Lg新能源 锂金属电池及包含该锂金属电池的电池模组和电池包

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976720A (zh) * 2003-05-20 2007-06-06 惠氏控股有限公司 用于治疗严重急性呼吸道综合征(sars)的组合物和方法
TW200811138A (en) * 2006-06-12 2008-03-01 Pfizer Prod Inc Pharmaceuticals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CN110982945B (zh) * 2020-03-04 2020-06-09 珠海丽珠试剂股份有限公司 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976720A (zh) * 2003-05-20 2007-06-06 惠氏控股有限公司 用于治疗严重急性呼吸道综合征(sars)的组合物和方法
TW200811138A (en) * 2006-06-12 2008-03-01 Pfizer Prod Inc Pharmaceuticals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAEZEH SADAT HOSSEINI等: "Simeprevir, potential candidate to repurpose for coronavirus infection:Virtual screening and molecular docking study", LIFE SCIENCES, 28 February 2020 (2020-02-28), pages 1 - 12 *
SURESH KUMAR: "COVID-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis", pages 1 - 8, Retrieved from the Internet <URL:https://doi:10.20944/preprints202003.0440.v1> *

Also Published As

Publication number Publication date
EP4146195A1 (en) 2023-03-15
JP2023539542A (ja) 2023-09-15
CA3177779A1 (en) 2021-11-11
AU2021269090A1 (en) 2022-12-01
KR20240073720A (ko) 2024-05-27
EP3906922A1 (en) 2021-11-10
WO2021224356A1 (en) 2021-11-11
US20230157994A1 (en) 2023-05-25
BR112022022578A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
CN116133657A (zh) 治疗covid-19疾病的新组合物和方法
US20210309733A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20220363746A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP5172679B2 (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
WO2023008530A1 (ja) 新型コロナウイルス感染症治療剤
US20230285510A1 (en) Treatment of coronavirus infection with interferon lambda
WO2021200651A1 (ja) コロナウイルス感染症治療剤
US20240317846A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230192872A1 (en) Tocilizumab for the treatment of viral infections
KR20230041097A (ko) SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
RU2837859C1 (ru) Лечение коронавирусной инфекции
US20230201308A1 (en) Treatment of coronavirus infection with interferon lambda
US20230109208A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
PRASAD et al. COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE
JP2021172601A (ja) コロナウイルス感染症治療・予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230516

WD01 Invention patent application deemed withdrawn after publication